US2017166891A1PendingUtilityA1

Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta

44
Assignee: BERG LLCPriority: May 25, 2012Filed: Nov 21, 2016Published: Jun 15, 2017
Est. expiryMay 25, 2032(~5.9 yrs left)· nominal 20-yr term from priority
Inventors:Niven Rajin NarainRangaprasad SarangarajanVivek K. VishnudasEnxuan Jing
A61P 3/10A61P 3/06G01N 33/6893A61K 31/19C12N 2310/14A61K 31/416A61K 31/4155G01N 2800/042C07K 14/4702C12N 15/113A61K 31/713G01N 33/5308A61P 3/04C12N 2310/11A61K 31/366C12Q 1/6883C07K 2317/76C07K 16/18A61K 31/7056Y10S977/907A61K 48/00
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods of treatment of metabolic syndrome with HSP90 inhibitors, particularly HSP90β inhibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using HSP90, particularly HSP90β, expression and activity level.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method of treating a metabolic syndrome in a subject, comprising administering to the subject a specific inhibitor of HSP90β, thereby treating the metabolic syndrome in the subject. 
     
     
         2 - 5 . (canceled) 
     
     
         6 . The method of  claim 1 , wherein the metabolic syndrome comprises type 2 diabetes. 
     
     
         7 . The method of  claim 1 , wherein the metabolic syndrome comprises type 1 diabetes. 
     
     
         8 . The method of  claim 1 , wherein the metabolic syndrome comprises insulin resistance. 
     
     
         9 . The method of  claim 1 , wherein the metabolic syndrome comprises insulin insufficiency. 
     
     
         10 . The method of  claim 1 , wherein the metabolic syndrome comprises obesity. 
     
     
         11 . The method of  claim 1 , wherein the metabolic syndrome comprises hyperinsulinemia. 
     
     
         12 . The method of  claim 1 , wherein the metabolic syndrome comprises impaired glucose tolerance (IGT). 
     
     
         13 . The method of  claim 1 , wherein a subject with metabolic syndrome exhibits three or more of the following signs:
 a) Blood pressure equal to or higher than 130/85 mmHg;   b) Fasting blood glucose equal to or higher than 100 mg/dL;   c) Large waist circumference wherein a large waist circumference is 40 inches or more for men and 35 inches or more for women;   d) Low HDL cholesterol wherein low LDH HDL cholesterol is under 40 mg/dL for men and under 50 mg/dL for women; and   e) Triglycerides equal to or higher than 150 mg/dL.   
     
     
         14 . The method of  claim 1 , wherein the specific inhibitor comprises a nucleic acid inhibitor. 
     
     
         15 - 17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the specific inhibitor comprises an antibody. 
     
     
         19 . The method of  claim 1 , wherein the specific inhibitor comprises a small molecule. 
     
     
         20 . The method of  claim 19 , wherein the small molecule is selected from the group consisting of lonidamine or an analog thereof, celastrol or analog thereof, gedunin or an analog thereof, and coumermycin or an analog thereof. 
     
     
         21 . The method of  claim 1 , wherein treating the metabolic syndrome comprises normalizing a blood glucose level in a subject. 
     
     
         22 . The method of  claim 1 , wherein treating the metabolic syndrome comprises normalizing an Hb1Ac level in a subject. 
     
     
         23 . The method of  claim 1 , wherein treating the metabolic syndrome comprises prevention of at least one complication of diabetes associated with poor circulation. 
     
     
         24 . The method of  claim 1 , wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of type 2 diabetes. 
     
     
         25 . The method of  claim 1 , wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of type 1 diabetes. 
     
     
         26 . The method of  claim 1 , wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of insulin resistance. 
     
     
         27 . The method of  claim 1 , wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of insulin insufficiency. 
     
     
         28 . The method of  claim 1 , wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of hyperinsulinemia. 
     
     
         29 . The method of  claim 1 , wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of impaired glucose tolerance (IGT). 
     
     
         30 . The method of  claim 1 , wherein treating the metabolic syndrome comprises amelioration of at least one sign or symptom of obesity. 
     
     
         31 . The method of  claim 1 , wherein treating the metabolic syndrome comprises amelioration of at least one of
 a) Blood pressure equal to or higher than 130/85 mmHg;   b) Fasting blood glucose equal to or higher than 100 mg/dL;   c) Large waist circumference wherein a large waist circumference is 40 inches or more for men and 35 inches or more for women;   d) Low HDL cholesterol wherein low HDL cholesterol is under 40 mg/dL for men and under 50 mg/dL for women; and   e) Triglycerides equal to or higher than 150 mg/dL.   
     
     
         32 . The method of  claim 31 , wherein treating the metabolic syndrome comprises amelioration of elevated blood pressure equal to or higher than 130/85 mmHg. 
     
     
         33 . The method of  claim 31 , wherein treating the metabolic syndrome comprises amelioration of elevated fasting blood glucose equal to or higher than 100 mg/dL. 
     
     
         34 . The method of  claim 31 , wherein treating the metabolic syndrome comprises amelioration of large waist circumference wherein a large waist circumference is 40 inches or more for men and 35 inches or more for women. 
     
     
         35 . The method of  claim 31 , wherein treating the metabolic syndrome comprises amelioration of low HDL cholesterol by increasing HDL cholesterol wherein low HDL cholesterol is under 40 mg/dL for men and under 50 mg/dL for women. 
     
     
         36 . The method of  claim 31 , wherein treating the metabolic syndrome comprises amelioration of elevated triglycerides equal to or higher than 150 mg/dL. 
     
     
         37 . The method of  claim 1 , wherein treating metabolic syndrome comprises amelioration of fatty liver. 
     
     
         38 . The method of  claim 1 , wherein treating metabolic syndrome comprises modulation of fat deposition. 
     
     
         39 - 51 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.